Conventus Orthopaedics acquired all assets of IntraFuse, including proprietary intramedullary implants for the minimally invasive repair of fibula and other fractures. The move marks the first step of Conventus’ intended expansion into lower extremity orthopedics. Transaction details were not disclosed.
IntraFuse’s FlexThread™ implants are FDA-cleared and protected by five issued and eight pending patents. The company is a start-up incubated by Surgical Frontiers, which recently divested certain assets to CrossRoads Extremity.
“Conventus is enthusiastic to expand beyond our innovative CAGE technology portfolio,” said Rick Epstein, CEO of Conventus Orthopaedics. “The FlexThread technology offers unique, minimally invasive and easy to use intramedullary products for small bone fractures. These products complement our intramedullary CAGE products for large bone peri-articular fractures. With the backing of our lead investor, Deerfield Management, this acquisition is a first step of what will be an aggressive transformation from a single product company into a formidable orthopaedic supplier. I have high expectations for continued business development activity coupled with development of proprietary devices.”
Conventus Orthopaedics acquired all assets of IntraFuse, including proprietary intramedullary implants for the minimally invasive repair of fibula and other fractures. The move marks the first step of Conventus' intended expansion into lower extremity orthopedics. Transaction details were not disclosed.
IntraFuse's FlexThread™...
Conventus Orthopaedics acquired all assets of IntraFuse, including proprietary intramedullary implants for the minimally invasive repair of fibula and other fractures. The move marks the first step of Conventus’ intended expansion into lower extremity orthopedics. Transaction details were not disclosed.
IntraFuse’s FlexThread™ implants are FDA-cleared and protected by five issued and eight pending patents. The company is a start-up incubated by Surgical Frontiers, which recently divested certain assets to CrossRoads Extremity.
“Conventus is enthusiastic to expand beyond our innovative CAGE technology portfolio,” said Rick Epstein, CEO of Conventus Orthopaedics. “The FlexThread technology offers unique, minimally invasive and easy to use intramedullary products for small bone fractures. These products complement our intramedullary CAGE products for large bone peri-articular fractures. With the backing of our lead investor, Deerfield Management, this acquisition is a first step of what will be an aggressive transformation from a single product company into a formidable orthopaedic supplier. I have high expectations for continued business development activity coupled with development of proprietary devices.”
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
